Definition and epidemiology
Mast cell activation syndrome (MCAS) is a clinical syndrome defined by recurrent episodes of mast cell mediator release producing symptoms in two or more organ systems, with objective evidence of mediator elevation and response to mast cell-directed therapy.
MCAS is distinct from systemic mastocytosis, in which there is clonal, neoplastic mast cell proliferation (often KIT D816V positive) with organ infiltration. MCAS has no clonal expansion in most cases (primary/idiopathic MCAS) though some patients have a small clonal population not meeting mastocytosis criteria (monoclonal mast cell activation syndrome, MMAS).
- True population prevalence is uncertain and debated; it is likely overdiagnosed in general practice and underdiagnosed in allergy/immunology specialty settings.
- Most commonly recognized in adults, more often women.
- Frequently coexists with hypermobile Ehlers-Danlos syndrome and postural orthostatic tachycardia syndrome (POTS), though causality is unproven.
- Many patients carry a prior history of atopy, chronic urticaria, or idiopathic anaphylaxis before diagnosis.
- MCAS requires: episodic symptoms + objective mediator rise + response to therapy — all three needed
- Tryptase must rise ≥20% + 2 ng/mL above the patient's own baseline during a flare
- MCAS has no clonal mast cell proliferation, unlike systemic mastocytosis
- KIT D816V mutation points away from idiopathic MCAS toward mastocytosis/MMAS
- Common triggers: heat, exercise, friction, NSAIDs, opioids, alcohol, stress
- First-line treatment is combined H1 + H2 antihistamines
- All patients with history of severe reactions need an epinephrine autoinjector
- Elevated baseline tryptase (>20 ng/mL) should prompt bone marrow evaluation for mastocytosis
Etiology and risk factors
MCAS is categorized by presumed mechanism:
- Primary (clonal) MCAS: a small, non-diagnostic population of abnormal mast cells (e.g., partial KIT mutation) lowers the activation threshold; overlaps with monoclonal mast cell activation syndrome.
- Secondary MCAS: mast cells are activated through a known immunologic trigger, most commonly IgE-mediated allergy (foods, venom, drugs) or physical triggers (heat, cold, friction, exercise).
- Idiopathic MCAS: no clonal or allergic trigger identified despite thorough workup.
Common reported triggers include:
- Physical stimuli: heat, cold, friction/pressure, exercise
- Medications: NSAIDs, opioids, vancomycin, radiocontrast agents, certain antibiotics
- Alcohol, stress, infections, and (in some patients) specific foods
Risk factors include a personal or family history of atopic disease, chronic urticaria, hypermobility spectrum disorders, and prior idiopathic anaphylaxis.
Pathophysiology
Mast cells reside in skin, GI mucosa, airways, and perivascular tissue. Upon activation (via IgE cross-linking of FcεRI, complement, neuropeptides, or direct physical stimuli), they degranulate and release preformed and newly synthesized mediators:
- Histamine — vasodilation, increased vascular permeability, pruritus, flushing
- Tryptase — the most useful clinical biomarker; released specifically from mast cells
- Leukotrienes and prostaglandins — bronchoconstriction, GI cramping
- Platelet-activating factor and cytokines (IL-6, TNF-alpha) — hypotension, systemic inflammation
In MCAS, mast cells have a lowered activation threshold or exaggerated response to otherwise subthreshold stimuli, producing episodic rather than constant symptoms. Unlike mastocytosis, there is no significant increase in mast cell number or tissue infiltration — the defect is functional/reactive, not proliferative.
Clinical features
Episodes are typically abrupt in onset, recurrent, and resolve within hours, often triggered by an identifiable stimulus. Symptoms affect two or more organ systems simultaneously during a flare:
- Cutaneous: flushing, urticaria, pruritus, angioedema
- Cardiovascular: hypotension, tachycardia, presyncope/syncope
- Respiratory: wheezing, throat tightness, nasal congestion
- Gastrointestinal: crampy abdominal pain, nausea, vomiting, diarrhea
- Neurologic/constitutional: headache, brain fog, fatigue
Between episodes, patients are often asymptomatic or have only mild baseline symptoms (chronic fatigue, mild GI complaints). The pattern is episodic and trigger-related rather than continuous, which helps distinguish MCAS from other chronic multisystem illnesses.
Diagnosis
Diagnosis is clinical and requires all three of the following (consensus criteria, most widely cited is the Valent/AAAAI-adjacent framework):
1. Typical episodic symptoms
Acute, recurrent symptoms involving at least two organ systems consistent with mast cell mediator release.
2. Objective laboratory evidence of mediator release
- Serum tryptase: drawn within 1-4 hours of symptom onset; must show an acute rise of at least 20% above the patient's own baseline plus 2 ng/mL
- Baseline tryptase should be measured when the patient is asymptomatic for comparison
- Other mediators (24-hour urine n-methylhistamine, prostaglandin D2/F2alpha metabolites) can support the diagnosis but are less specific
3. Response to mast cell-directed therapy
Symptomatic improvement with antihistamines or other mast cell stabilizing/mediator-blocking agents.
Additional workup to exclude mimics and clonal disease:
- Baseline tryptase >20 ng/mL warrants evaluation for systemic mastocytosis (bone marrow biopsy, KIT D816V testing)
- Skin or serum IgE testing if an allergic trigger is suspected
- Exclude pheochromocytoma, carcinoid syndrome, and other causes of episodic flushing/hypotension
A single elevated tryptase without temporal correlation to symptoms, or persistently normal tryptase during flares, argues against the diagnosis.
Differential diagnosis
| Condition | Distinguishing feature |
|---|---|
| Systemic mastocytosis | Clonal mast cell proliferation, elevated baseline tryptase, KIT D816V, skin/bone marrow infiltration |
| Idiopathic anaphylaxis | Severe, recurrent multisystemic reaction (skin/mucosal plus respiratory or cardiovascular involvement) with no identifiable trigger; heavily overlaps with idiopathic MCAS |
| Carcinoid syndrome | Flushing with diarrhea, elevated urinary 5-HIAA, associated with neuroendocrine tumor |
| Pheochromocytoma | Episodic hypertension, headache, diaphoresis; elevated plasma/urine catecholamines |
Management
Management is largely supportive and stepwise, guided by allergy/immunology consensus statements (no single universally endorsed guideline exists, but approach is broadly consistent across US/European expert groups):
Trigger avoidance
- Identify and avoid personal physical, dietary, or pharmacologic triggers
- Avoid known mast cell-degranulating drugs (certain opioids, NSAIDs if sensitive, IV vancomycin, radiocontrast without premedication) when possible
Pharmacologic therapy (stepwise)
- H1 antihistamines (second-generation preferred for daily use) — first-line for flushing/pruritus
- H2 antihistamines — added for GI symptoms
- Leukotriene receptor antagonists (montelukast) — for refractory GI/respiratory symptoms
- Mast cell stabilizers (cromolyn sodium, oral) — particularly for GI-predominant disease
- Low-dose aspirin — may reduce prostaglandin-mediated flushing in select patients (requires caution, as aspirin itself can trigger mast cell activation in some)
- Omalizumab (anti-IgE) — considered in refractory cases, particularly with an allergic/IgE component
Emergency preparedness
- All patients with a history of severe reactions (hypotension, airway involvement) should carry an epinephrine autoinjector
- Patients should have a written emergency action plan
What is not indicated
- Tyrosine kinase inhibitors (e.g., imatinib) are reserved for clonal/neoplastic mast cell disease (mastocytosis), not idiopathic MCAS
- Systemic corticosteroids are not first-line but may be used short-term for severe refractory flares
Complications and prognosis
- Recurrent anaphylaxis or near-anaphylactic episodes carry risk of hypoxic injury or death if untreated
- Chronic symptom burden can significantly impair quality of life and is associated with anxiety/depression
- Progression to systemic mastocytosis is not expected in true idiopathic MCAS, though patients with monoclonal MCAS warrant periodic reassessment
- With trigger identification and stepwise pharmacologic therapy, most patients achieve meaningful symptom control; complete remission is uncommon but severe episodes typically become less frequent over time
MCAS = "3 T's": Trigger (episodic), Tryptase rise (objective), Treatment response (confirmatory)
Practice questions
1. A 34-year-old woman presents with recurrent episodes of flushing, hives, and lightheadedness occurring several times a month, each lasting 1-2 hours and often triggered by hot showers or exercise. Between episodes she feels well. Serum tryptase drawn during a flare is 15 ng/mL; baseline tryptase measured weeks later while asymptomatic is 6 ng/mL. Her symptoms improve substantially with scheduled H1 and H2 antihistamines. Which of the following best supports the diagnosis of mast cell activation syndrome over systemic mastocytosis?
2. A 29-year-old man with a history of idiopathic anaphylaxis undergoes workup for suspected MCAS. His baseline tryptase (measured when asymptomatic) is 28 ng/mL. During a subsequent flare with flushing and hypotension, repeat tryptase is 32 ng/mL. Which of the following is the most appropriate next step?
3. A 41-year-old woman with suspected MCAS has frequent flares with flushing, abdominal cramping, and diarrhea despite being on a second-generation H1 antihistamine. She has no history of severe hypotension or airway compromise. Which medication should be added next according to a stepwise approach?
Frequently asked questions
What causes mast cell activation syndrome?
MCAS results from mast cells releasing excessive mediators like histamine and tryptase in response to triggers such as heat, exercise, friction, certain medications (NSAIDs, opioids), alcohol, or stress. In primary MCAS, a small abnormal mast cell population lowers the activation threshold; in secondary MCAS, an identifiable allergic or physical trigger is present; in idiopathic MCAS, no clear cause is found despite thorough testing.
What are the first symptoms of MCAS?
Episodes typically begin abruptly with flushing, hives, or itching, often accompanied by abdominal cramping, nausea, lightheadedness, or a feeling of throat tightness. Symptoms usually involve two or more body systems at once and resolve within hours. Between episodes, many people feel relatively well or have only mild background fatigue or GI discomfort.
How is MCAS diagnosed?
Diagnosis requires three things together: recurrent episodic symptoms affecting multiple organ systems, a documented rise in serum tryptase (or other mediators) during a symptomatic episode compared to the person's baseline, and improvement with antihistamines or other mast cell-targeted treatment. Doctors also rule out systemic mastocytosis and other causes of similar symptoms like carcinoid syndrome or pheochromocytoma.
Is MCAS curable?
There is no definitive cure for MCAS, but it is very manageable for most people. Treatment focuses on avoiding personal triggers and using antihistamines, mast cell stabilizers, or other mediator-blocking medications to reduce the frequency and severity of episodes. Many patients see significant improvement over time, though occasional flares may still occur.
MCAS vs systemic mastocytosis — what is the difference?
The key difference is that systemic mastocytosis involves an actual clonal, abnormal increase in mast cell numbers (often with a KIT D816V mutation) that infiltrate organs like bone marrow and skin, with a persistently elevated baseline tryptase. MCAS, in contrast, has normal mast cell numbers and typically normal baseline tryptase, with episodic rather than constant mediator release and no proliferative or neoplastic process.
Key drugs
Related conditions and differentials
Sources and further reading
StatPearls (NCBI Bookshelf)MedlinePlusWHO ICD-10: D89.8
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.